MCID: PDT042
MIFTS: 48

Pediatric Hepatocellular Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Pediatric Hepatocellular Carcinoma

MalaCards integrated aliases for Pediatric Hepatocellular Carcinoma:

Name: Pediatric Hepatocellular Carcinoma 12 54 60
Childhood Hepatocellular Carcinoma 12 54 6
Childhood-Onset Hepatocellular Carcinoma 60
Childhood Carcinoma of Liver Cell 54
Pediatric Carcinoma of Liver Cell 54
Childhood Liver Cell Carcinoma 54
Pediatric Liver Cell Carcinoma 54
Childhood-Onset Hcc 60
Childhood Hepatoma 54
Pediatric Hepatoma 54
Pediatric Hcc 60

Characteristics:

Orphanet epidemiological data:

60
pediatric hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),<1/1000000 (United States); Age of onset: Adolescent,Childhood; Age of death: adolescent,adult,early childhood,late childhood,young Adult;

Classifications:

Orphanet: 60  
Rare hepatic diseases


External Ids:

Disease Ontology 12 DOID:0070322
NCIt 51 C7955
ICD10 via Orphanet 35 C22.0
Orphanet 60 ORPHA33402

Summaries for Pediatric Hepatocellular Carcinoma

NIH Rare Diseases : 54 Childhood hepatocellular carcinoma (childhood HCC) is a rare type of malignant (cancerous) tumor that forms in the cells and tissues of the liver. Childhood HCC is usually found in older children and adolescents (10-14 years), but has been found in children younger than 5. Symptoms may include a mass in the abdomen, a swollen and painful abdomen, weight loss, poor appetite, yellowing of the skin and eyes (jaundice), vomiting, fever, itchy skin, and a decreased number of red blood cells (anemia). The cause of childhood HCC is not well understood; however, underlying disorders that cause liver dysfunction (ex. hepatitis B) and congenital or genetic disorders that affect the liver (ex. tyrosinemia type 1) may increase the risk for childhood HCC to occur. Treatment options vary depending on a variety of factors including the stage of the cancer and may include surgery to remove the tumor and chemotherapy.

MalaCards based summary : Pediatric Hepatocellular Carcinoma, also known as childhood hepatocellular carcinoma, is related to hepatocellular carcinoma and hepatitis. An important gene associated with Pediatric Hepatocellular Carcinoma is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Mesodermal Commitment Pathway. The drugs Doxorubicin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and eye, and related phenotypes are hepatomegaly and abdominal pain

Disease Ontology : 12 A hepatocellular carcinoma that occurs in children and is characterized by a distinct etiological predisposition, biological behavior, and lower frequency of cirrhosis as compared to adult hepatocellular carcinoma.

Related Diseases for Pediatric Hepatocellular Carcinoma

Diseases related to Pediatric Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 18)
# Related Disease Score Top Affiliating Genes
1 hepatocellular carcinoma 29.9 CTNNB1 MET YAP1
2 hepatitis 10.2
3 hepatitis b 10.2
4 pilomatrixoma 9.9 CTNNB1 YAP1
5 liver cirrhosis 9.8
6 thrombocytosis 9.8
7 hepatoblastoma 9.8
8 sarcoma, synovial 9.8 CTNNB1 MET
9 stomach disease 9.8 CTNNB1 MET
10 respiratory system cancer 9.8 CTNNB1 MET
11 breast ductal carcinoma 9.7 CTNNB1 MET
12 gastrointestinal system cancer 9.7 CTNNB1 MET
13 large intestine cancer 9.7 CTNNB1 MET
14 pancreas adenocarcinoma 9.6 CTNNB1 MET
15 squamous cell carcinoma, head and neck 9.5 CTNNB1 MET
16 cholangiocarcinoma 9.5 CTNNB1 MET YAP1
17 gastric adenocarcinoma 9.5 CTNNB1 MET YAP1
18 gastric cancer 9.3 CTNNB1 MET YAP1

Graphical network of the top 20 diseases related to Pediatric Hepatocellular Carcinoma:



Diseases related to Pediatric Hepatocellular Carcinoma

Symptoms & Phenotypes for Pediatric Hepatocellular Carcinoma

Human phenotypes related to Pediatric Hepatocellular Carcinoma:

60 33 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hepatomegaly 60 33 hallmark (90%) Very frequent (99-80%) HP:0002240
2 abdominal pain 60 33 hallmark (90%) Very frequent (99-80%) HP:0002027
3 hepatic fibrosis 60 33 hallmark (90%) Very frequent (99-80%) HP:0001395
4 elevated alpha-fetoprotein 60 33 hallmark (90%) Very frequent (99-80%) HP:0006254
5 vomiting 60 33 frequent (33%) Frequent (79-30%) HP:0002013
6 fatigue 60 33 frequent (33%) Frequent (79-30%) HP:0012378
7 epigastric pain 60 33 frequent (33%) Frequent (79-30%) HP:0410019
8 portal vein thrombosis 60 33 frequent (33%) Frequent (79-30%) HP:0030242
9 hepatic necrosis 60 33 frequent (33%) Frequent (79-30%) HP:0002605

GenomeRNAi Phenotypes related to Pediatric Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 9.23 MET
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.23 MET
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-150 9.23 MET
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.23 CTNNB1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.23 CTNNB1 MET
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-38 9.23 MET
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-98 9.23 MET

MGI Mouse Phenotypes related to Pediatric Hepatocellular Carcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.58 CTNNB1 MET YAP1
2 embryo MP:0005380 9.54 CTNNB1 MET YAP1
3 liver/biliary system MP:0005370 9.5 CTNNB1 MET YAP1
4 muscle MP:0005369 9.43 CTNNB1 MET YAP1
5 neoplasm MP:0002006 9.33 CTNNB1 MET YAP1
6 renal/urinary system MP:0005367 9.13 CTNNB1 MET YAP1
7 respiratory system MP:0005388 8.8 CTNNB1 MET YAP1

Drugs & Therapeutics for Pediatric Hepatocellular Carcinoma

Drugs for Pediatric Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
3
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
4
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 43805 6857599 5310940 9887054
5
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
6
Sorafenib Approved, Investigational Phase 2, Phase 3,Not Applicable 284461-73-0 216239 406563
7
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
8
Irinotecan Approved, Investigational Phase 2, Phase 3 100286-90-6, 97682-44-5 60838
9
Vincristine Approved, Investigational Phase 2, Phase 3 2068-78-2, 57-22-7 5978
10
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
11
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
12
Doxil Approved June 1999 Phase 3,Phase 2 31703
13 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
14 Anti-Bacterial Agents Phase 3,Phase 2
15 Antibiotics, Antitubercular Phase 3,Phase 2
16 Topoisomerase Inhibitors Phase 3,Phase 2
17 Anti-Infective Agents Phase 2, Phase 3
18 Immunologic Factors Phase 2, Phase 3
19 Immunosuppressive Agents Phase 2, Phase 3
20 Antimetabolites, Antineoplastic Phase 2, Phase 3
21 Antiviral Agents Phase 2, Phase 3
22 Antimetabolites Phase 2, Phase 3
23 Protein Kinase Inhibitors Phase 2, Phase 3,Not Applicable
24 Antimitotic Agents Phase 2, Phase 3
25 topoisomerase I inhibitors Phase 2, Phase 3
26 Etoposide phosphate Phase 2, Phase 3
27 Dermatologic Agents Phase 2, Phase 3
28 Keratolytic Agents Phase 2, Phase 3
29 Antineoplastic Agents, Phytogenic Phase 2, Phase 3
30 Podophyllotoxin Phase 2, Phase 3 518-28-5
31
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
32
leucovorin Approved Phase 2 58-05-9 143 6006
33
Trametinib Approved Phase 2 871700-17-3 11707110
34
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
35
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
36
Melphalan Approved Phase 2 148-82-3 460612 4053
37
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
39
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
40 Interferon-alpha Phase 2
41 interferons Phase 2
42 Interferon alpha-2 Phase 2
43 Antineoplastic Agents, Alkylating Phase 2
44 Alkylating Agents Phase 2
45 Antirheumatic Agents Phase 2
46 Angiogenesis Inhibitors Phase 2
47 Angiogenesis Modulating Agents Phase 2
48 Calcium, Dietary Phase 2
49 Vitamin B Complex Phase 2
50 Protective Agents Phase 2

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Chemotherapy in Treating Children With Liver Cancer Completed NCT00003912 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride
2 Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery Recruiting NCT03533582 Phase 2, Phase 3 Carboplatin;Cisplatin;Doxorubicin;Etoposide;Fluorouracil;Gemcitabine;Irinotecan;Oxaliplatin;Sorafenib;Vincristine Sulfate
3 Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery Unknown status NCT00471484 Phase 2 doxorubicin hydrochloride;fluorouracil;oxaliplatin
4 Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer Unknown status NCT00276705 Phase 2 cisplatin;cyclophosphamide;doxorubicin hydrochloride;thalidomide
5 Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Completed NCT02042443 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Trametinib
6 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
7 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
8 Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases Completed NCT00019786 Phase 2 isolated perfusion;melphalan
9 Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Completed NCT00161187 Phase 1
10 Collecting and Storing Tissue From Young Patients With Cancer Completed NCT00898755
11 Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Active, not recruiting NCT02072486 Not Applicable Sorafenib Tosylate
12 Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer Withdrawn NCT00899002

Search NIH Clinical Center for Pediatric Hepatocellular Carcinoma

Genetic Tests for Pediatric Hepatocellular Carcinoma

Anatomical Context for Pediatric Hepatocellular Carcinoma

MalaCards organs/tissues related to Pediatric Hepatocellular Carcinoma:

42
Skin, Liver, Eye, Bone, Thyroid, Pancreas

Publications for Pediatric Hepatocellular Carcinoma

Articles related to Pediatric Hepatocellular Carcinoma:

(show all 29)
# Title Authors Year
1
Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation. ( 30977242 )
2019
2
Predisposing Conditions to Pediatric Hepatocellular Carcinoma and Association With Outcomes: Single-center Experience. ( 30676520 )
2019
3
Orthotopic Liver Transplantation After Stereotactic Body Radiotherapy for Pediatric Hepatocellular Carcinoma with Central Biliary Obstruction and Nodal Involvement. ( 30648040 )
2018
4
Pediatric hepatocellular carcinoma. ( 30254403 )
2018
5
Pediatric hepatocellular carcinoma: challenges and solutions. ( 28144610 )
2017
6
Stereotactic body radiotherapy for pediatric hepatocellular carcinoma with central biliary obstruction. ( 28436210 )
2017
7
Management of pediatric hepatocellular carcinoma: A multimodal approach. ( 28631359 )
2017
8
Pediatric hepatocellular carcinoma in a developing country: Is the etiology changing? ( 27392999 )
2016
9
YAP Subcellular Localization and Hippo Pathway Transcriptome Analysis in Pediatric Hepatocellular Carcinoma. ( 27605415 )
2016
10
Cause and effect: the etiology of pediatric hepatocellular carcinoma and the role for liver transplantation. ( 27726261 )
2016
11
Distinct set of chromosomal aberrations in childhood hepatocellular carcinoma is correlated to hepatitis B virus infection. ( 26837720 )
2016
12
Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma. ( 25447203 )
2015
13
Transarterial embolization for pediatric hepatocellular carcinoma with cardiac cirrhosis. ( 26013052 )
2015
14
Childhood hepatocellular carcinoma: a clinicopathological study of 12 cases with special reference to EpCAM. ( 24138022 )
2014
15
Radioembolisation for treatment of pediatric hepatocellular carcinoma. ( 23212597 )
2013
16
Approach to pediatric hepatocellular carcinoma. ( 30992867 )
2013
17
Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. ( 21922643 )
2012
18
Characterisation of the cell line HC-AFW1 derived from a pediatric hepatocellular carcinoma. ( 22666492 )
2012
19
Clinical characteristics and prognosis of pediatric hepatocellular carcinoma. ( 16369702 )
2006
20
Virchows node: rare presentation of childhood hepatocellular carcinoma. ( 15758545 )
2005
21
Adult type vs. Childhood hepatocellular carcinoma--are they the same or different lesions? Biology, natural history, prognosis, and treatment. ( 12228910 )
2002
22
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. ( 9927037 )
1999
23
Pretransplant chemotherapy in pediatric hepatocellular carcinoma. ( 7807316 )
1994
24
Analysis of integrated hepatitis B virus DNA and flanking cellular sequences in a childhood hepatocellular carcinoma. ( 8006642 )
1994
25
Latent hepatitis B virus infection in childhood hepatocellular carcinoma. Analysis by polymerase chain reaction. ( 1315210 )
1992
26
Childhood hepatocellular carcinoma and hepatoblastoma: integrated sonography and dynamic CT. ( 1667465 )
1991
27
Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. ( 2553245 )
1989
28
Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. Report of 51 cases strongly associated with rapid development of liver cirrhosis. ( 2828461 )
1987
29
Hepatitis B related childhood hepatocellular carcinoma. Childhood hepatic malignancies. ( 3036330 )
1987

Variations for Pediatric Hepatocellular Carcinoma

ClinVar genetic disease variations for Pediatric Hepatocellular Carcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MET NM_001127500.2(MET): c.3572C> T (p.Thr1191Ile) single nucleotide variant Pathogenic rs121913675 GRCh37 Chromosome 7, 116419007: 116419007
2 MET NM_001127500.2(MET): c.3572C> T (p.Thr1191Ile) single nucleotide variant Pathogenic rs121913675 GRCh38 Chromosome 7, 116778953: 116778953
3 MET NM_001127500.2(MET): c.3804G> A (p.Met1268Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913676 GRCh37 Chromosome 7, 116423475: 116423475
4 MET NM_001127500.2(MET): c.3804G> A (p.Met1268Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913676 GRCh38 Chromosome 7, 116783421: 116783421
5 MET NM_001127500.2(MET): c.3785A> G (p.Lys1262Arg) single nucleotide variant Pathogenic rs121913677 GRCh37 Chromosome 7, 116423456: 116423456
6 MET NM_001127500.2(MET): c.3785A> G (p.Lys1262Arg) single nucleotide variant Pathogenic rs121913677 GRCh38 Chromosome 7, 116783402: 116783402

Cosmic variations for Pediatric Hepatocellular Carcinoma:

9 (show top 50) (show all 3417)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1626018 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 0
2 COSM1615665 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 0
3 COSM1602238 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 0
4 COSM6951673 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 0
5 COSM1616325 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 0
6 COSM3707827 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 0
7 COSM3707828 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 0
8 COSM1623051 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 0
9 COSM1612127 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 0
10 COSM1618451 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581L 4:145885684-145885684 0
11 COSM1611545 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 0
12 COSM1612685 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47V 19:52002156-52002156 0
13 COSM1612018 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 0
14 COSM1618219 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 0
15 COSM1624399 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 0
16 COSM1609798 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 0
17 COSM1605856 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 0
18 COSM1602404 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 0
19 COSM1607880 ZFYVE26 liver,NS,carcinoma,hepatocellular carcinoma c.663C>A p.A221A 14:67807621-67807621 0
20 COSM3661787 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.2882C>T p.P961L 5:32364229-32364229 0
21 COSM1270878 ZFP36L2 liver,NS,carcinoma,hepatocellular carcinoma c.910T>G p.S304A 2:43224894-43224894 0
22 COSM1612900 ZFP28 liver,NS,carcinoma,hepatocellular carcinoma c.1865G>A p.C622Y 19:56554650-56554650 0
23 COSM3663890 ZFHX4 liver,NS,carcinoma,hepatocellular carcinoma c.10601C>G p.S3534C 8:76864315-76864315 0
24 COSM6969923 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.10852C>A p.P3618T 16:72787424-72787424 0
25 COSM3717069 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.8342A>G p.Q2781R 16:72794340-72794340 0
26 COSM6219678 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.9997C>T p.Q3333* 16:72788279-72788279 0
27 COSM1613453 ZEB2 liver,NS,carcinoma,hepatocellular carcinoma c.1141A>G p.M381V 2:144400046-144400046 0
28 COSM3717124 ZCCHC14 liver,NS,carcinoma,hepatocellular carcinoma c.71A>T p.Q24L 16:87491757-87491757 0
29 COSM1608898 ZC3H7A liver,NS,carcinoma,hepatocellular carcinoma c.2866A>G p.N956D 16:11751367-11751367 0
30 COSM3705381 ZBTB41 liver,NS,carcinoma,hepatocellular carcinoma c.1700G>A p.R567K 1:197178489-197178489 0
31 COSM1601838 ZBTB40 liver,NS,carcinoma,hepatocellular carcinoma c.3339C>A p.F1113L 1:22524258-22524258 0
32 COSM1610770 ZBTB4 liver,NS,carcinoma,hepatocellular carcinoma c.454G>T p.G152C 17:7466348-7466348 0
33 COSM1601260 ZBTB37 liver,NS,carcinoma,hepatocellular carcinoma c.620G>C p.S207T 1:173870845-173870845 0
34 COSM1624206 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2136A>G p.T712T 8:80518852-80518852 0
35 COSM1624207 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2311A>G p.I771V 8:80519295-80519295 0
36 COSM1616586 ZBED4 liver,NS,carcinoma,hepatocellular carcinoma c.2225A>C p.E742A 22:49885887-49885887 0
37 COSM1624117 YTHDF3 liver,NS,carcinoma,hepatocellular carcinoma c.1568A>G p.N523S 8:63187582-63187582 0
38 COSM1603361 YME1L1 liver,NS,carcinoma,hepatocellular carcinoma c.2006A>G p.H669R 10:27116230-27116230 0
39 COSM6982918 YES1 skin,eye,carcinoma,NS c.851G>A p.G284E 18:743289-743289 0
40 COSM1617254 YEATS2 liver,NS,carcinoma,hepatocellular carcinoma c.501C>T p.N167N 3:183722100-183722100 0
41 COSM3663693 XPO7 liver,NS,carcinoma,hepatocellular carcinoma c.806A>G p.Y269C 8:21977812-21977812 0
42 COSM1609152 XPO6 liver,NS,carcinoma,hepatocellular carcinoma c.882C>T p.G294G 16:28156289-28156289 0
43 COSM6957749 XPO1 liver,NS,carcinoma,hepatocellular carcinoma c.301+1G>C p.? 2:61522610-61522610 0
44 COSM1624082 XKR4 liver,NS,carcinoma,hepatocellular carcinoma c.1076A>G p.D359G 8:55523350-55523350 0
45 COSM1613650 XIRP2 liver,NS,carcinoma,hepatocellular carcinoma c.9350G>C p.R3117P 2:167250742-167250742 0
46 COSM3660541 XIRP1 liver,NS,carcinoma,hepatocellular carcinoma c.142C>A p.Q48K 3:39189304-39189304 0
47 COSM1625463 XIAP liver,NS,carcinoma,hepatocellular carcinoma c.493G>T p.A165S 23:123886155-123886155 0
48 COSM3663909 WWP1 liver,NS,carcinoma,hepatocellular carcinoma c.210-2A>G p.? 8:86381503-86381503 0
49 COSM1625309 WWC3 liver,NS,carcinoma,hepatocellular carcinoma c.1121C>A p.S374Y 23:10117180-10117180 0
50 COSM1621161 WTAP liver,NS,carcinoma,hepatocellular carcinoma c.283C>T p.Q95* 6:159748200-159748200 0

Expression for Pediatric Hepatocellular Carcinoma

Search GEO for disease gene expression data for Pediatric Hepatocellular Carcinoma.

Pathways for Pediatric Hepatocellular Carcinoma

Pathways related to Pediatric Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.68 CTNNB1 MET YAP1
2
Show member pathways
12.05 CTNNB1 YAP1
3
Show member pathways
11.98 CTNNB1 MET
4 11.85 CTNNB1 MET
5 11.8 CTNNB1 YAP1
6 11.71 CTNNB1 YAP1
7 11.68 MET YAP1
8 11.57 CTNNB1 MET
9 11.56 MET YAP1
10
Show member pathways
11.37 CTNNB1 MET
11 11.24 CTNNB1 MET
12 11.18 CTNNB1 MET
13 10.96 CTNNB1 YAP1
14 10.87 CTNNB1 MET
15 10.76 CTNNB1 MET
16 10.56 CTNNB1 MET
17 10.1 CTNNB1 MET

GO Terms for Pediatric Hepatocellular Carcinoma

Cellular components related to Pediatric Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor complex GO:0005667 8.62 CTNNB1 YAP1

Biological processes related to Pediatric Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.58 CTNNB1 MET YAP1
2 regulation of gene expression GO:0010468 9.48 CTNNB1 YAP1
3 Wnt signaling pathway GO:0016055 9.46 CTNNB1 MET
4 regulation of cell proliferation GO:0042127 9.43 CTNNB1 YAP1
5 vasculogenesis GO:0001570 9.32 CTNNB1 YAP1
6 regulation of neurogenesis GO:0050767 9.26 CTNNB1 YAP1
7 regulation of canonical Wnt signaling pathway GO:0060828 9.16 CTNNB1 YAP1
8 cell proliferation GO:0008283 9.13 CTNNB1 MET YAP1
9 positive regulation of MAPK cascade GO:0043410 9.07 CTNNB1
10 entry of bacterium into host cell GO:0035635 8.62 CTNNB1 MET

Molecular functions related to Pediatric Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription coactivator activity GO:0003713 9.16 CTNNB1 YAP1
2 protein C-terminus binding GO:0008022 8.96 CTNNB1 YAP1
3 protein phosphatase binding GO:0019903 8.62 CTNNB1 MET

Sources for Pediatric Hepatocellular Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....